CT‑1042, a novel anticancer agent, exhibits effects by activating p53 and inhibiting survivin

Yang,Jun; Li,Linna; Xu,Chengwang; Yang,Dexuan; Wang,Shanshan; Yuan,Shoujun

doi:10.3892/or.2018.6354

CT‑1042, a novel anticancer agent, exhibits effects by activating p53 and inhibiting survivin

Authors:
- Jun Yang
- Linna Li
- Chengwang Xu
- Dexuan Yang
- Shanshan Wang
- Shoujun Yuan
View Affiliations

Affiliations: School of Graduate Studies, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China, School of Graduate Studies, Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: April 4, 2018 https://doi.org/10.3892/or.2018.6354
Pages: 2759-2768

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A novel small molecular compound, 4‑ethyl‑8‑fluoro‑hydroxy‑9‑methoxy‑11‑methyl‑1,12‑dihydro‑4H‑2‑oxa‑6,12a‑diaza‑dibenzo[b,h]fluorene‑3,13‑dione (CT‑1042) exhibits potent antitumor activity against many tumor cells in vitro. However, the effects and underlying mechanisms of CT‑1042 in non‑small cell lung cancer (NSCLC) remain unclear. The present study was designed to determine the anticancer properties and underlying molecular mechanisms of CT‑1042 in NCI‑H460 NSCLC cells. A thiazolyl blue tetrazolium bromide assay (MTT) was performed to evaluate cell viability and flow cytometry was used to analyze apoptosis, mitochondrial membrane potential (MMP) and cell cycle. Real‑time quantitative PCR and western blotting were conducted to determine relative mRNA and protein levels. A tumor xenograft experiment was performed to investigate the effects of CT‑1042 on tumor growth in vivo. CT‑1042 markedly inhibited the proliferation of twelve cancer cell lines, decreased MMP in subject cells and increased caspase‑3 activity. Cell cycle analysis indicated that CT‑1042 delayed the cell cycle progression during the G2/M phase in a dose‑dependent manner. In addition, CT‑1042 induced mitochondrial‑mediated apoptosis by activating p53 and Bax, as well as inhibiting Bcl‑2 and survivin. Finally, CT‑1042 significantly suppressed NCI‑H460 xenograft tumor growth in vivo, with low systemic toxicity. Collectively, these results revealed that CT‑1042 has significant lung anticancer properties.

View Figures

View References

1	Wall ME and Wani MC: Camptothecin and taxol: From discovery to clinic. J Ethnopharmacol. 51:239–254. 1996. View Article : Google Scholar : PubMed/NCBI
2	Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS Jr, Silber R and Potmesil M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 51:3052–3055. 1991.PubMed/NCBI
3	Martino E, Della Volpe S, Terribile E, Benetti E, Sakaj M, Centamore A, Sala A and Collina S: The long story of camptothecin: from traditional medicine to drugs. Bioorg Med Chem Lett. 27:701–707. 2017. View Article : Google Scholar : PubMed/NCBI
4	Ryan JJ: Tyrosine kinase inhibitors in pulmonary vascular disease. JACC Basic Transl Sci. 1:684–686. 2016. View Article : Google Scholar
5	Rahman Jazieh A, Abdelhafiez N, Al Olayan A, Bamefleh H and Loutfi S: Tyrosine kinase inhibitors: What after complete remission of lung cancer? Cancer Treat Res Commun. 11:17–20. 2017. View Article : Google Scholar
6	Cayssials E and Guilhot F: Beyond tyrosine kinase inhibitors: Combinations and other agents. Best Pract Res Clin Haematol. 29:271–283. 2016. View Article : Google Scholar : PubMed/NCBI
7	Lin Z, Zhang Q and Luo W: Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions. Eur J Pharmacol. 793:76–81. 2016. View Article : Google Scholar : PubMed/NCBI
8	Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, et al: Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 35 Suppl:S224–S243. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kise K, Kinugasa-Katayama Y and Takakura N: Tumor microenvironment for cancer stem cells. Adv Drug Deliv Rev. 99:197–205. 2016. View Article : Google Scholar : PubMed/NCBI
10	Umesalma S, Nagendraprabhu P and Sudhandiran G: Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells. Mol Cell Biochem. 399:303–313. 2015. View Article : Google Scholar : PubMed/NCBI
11	Tyagi A, Singh RP, Agarwal C and Agarwal R: Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: Evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis. 27:2269–2280. 2006. View Article : Google Scholar : PubMed/NCBI
12	Chargari C, Leteur C, Angevin E, Bashir T, Schoentjes B, Arts J, Janicot M, Bourhis J and Deutsch E: Preclinical assessment of JNJ-26854165 (Serdemetan1), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 312:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wang H and Yan C: A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia. 13:611–619. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hasanzadeh M, Shadjou N and de la Guardia M: Current advancement in immunosensing of p53 tumor suppressor protein based on nanomaterials: Analytical approach. TrAC Trends in Analyt Chem. 89:13–20. 2017. View Article : Google Scholar
15	Enoch T and Norbury C: Cellular responses to DNA damage: Cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 20:426–430. 1995. View Article : Google Scholar : PubMed/NCBI
16	Lazo PA: Reverting p53 activation after recovery of cellular stress to resume with cell cycle progression. Cell Signal. 33:49–58. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zeng L, Li T, Xu DC, Liu J, Mao G, Cui MZ, Fu X and Xu X: Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein. J Biol Chem. 287:29125–29133. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ha M, Wei L, Guan X, Li L and Liu C: p53-dependent apoptosis contributes to di-(2-ethylhexyl) phthalate-induced hepatotoxicity. Environ Pollut. 208:416–425. 2016. View Article : Google Scholar : PubMed/NCBI
19	Gao CF, Ren S, Zhang L, Nakajima T, Ichinose S, Hara T, Koike K and Tsuchida N: Caspase-dependent cytosolic release of cytochrome c and membrane translocation of bax in p53-induced apoptosis. Exp Cell Res. 265:145–151. 2001. View Article : Google Scholar : PubMed/NCBI
20	Feng JH: Establishment of a cell strain from human kidney cell carcinoma KCC-853. Zhonghua Bing Li Xue Za Zhi. 17:102–104. 1988.(In Chinese). PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lopez J and Tait SW: Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer. 112:957–962. 2015. View Article : Google Scholar : PubMed/NCBI
23	Yuan H, Cao Y, Li L, Wang S, Yang D, Zhong X, Tang S and Yuan S: SM-1 induces apoptosis of BGC-823 cells by activating procaspase-3 and exerts antitumor effect. Mil Med Sci. 40:326–330. 2016.
24	Barre B and Perkins ND: A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J. 26:4841–4855. 2007. View Article : Google Scholar : PubMed/NCBI
25	Fu Y, Kadioglu O, Wiench B, Wei Z, Gao C, Luo M, Gu C, Zu Y and Efferth T: Cell cycle arrest and induction of apoptosis by cajanin stilbene acid from Cajanus cajan in breast cancer cells. Phytomedicine. 22:462–468. 2015. View Article : Google Scholar : PubMed/NCBI
26	Li Y, Yang F, Zheng W, Hu M, Wang J, Ma S, Deng Y, Luo Y, Ye T and Yin W: Punica granatum (pomegranate) leaves extract induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in non-small cell lung cancer in vitro. Biomed Pharmacother. 80:227–235. 2016. View Article : Google Scholar : PubMed/NCBI
27	Pasetto LM, D'Andrea MR, Brandes AA, Rossi E and Monfardini S: The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol. 60:59–75. 2006. View Article : Google Scholar : PubMed/NCBI
28	Voland C, Bord A, Peleraux A, Penarier G, Carriere D, Galiegue S, Cvitkovic E, Jbilo O and Casellas P: Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther. 5:2149–2157. 2006. View Article : Google Scholar : PubMed/NCBI
29	Saralamma VV, Nagappan A, Hong GE, Lee HJ, Yumnam S, Raha S, Heo JD, Lee SJ, Lee WS, Kim EH and Kim GS: Poncirin induces apoptosis in AGS human gastric cancer cells through extrinsic apoptotic pathway by up-regulation of Fas ligand. Int J Mol Sci. 16:22676–22691. 2015. View Article : Google Scholar : PubMed/NCBI
30	Kee JY, Han YH, Kim DS, Mun JG, Park J, Jeong MY, Um JY and Hong SH: Inhibitory effect of quercetin on colorectal lung metastasis through inducing apoptosis, and suppression of metastatic ability. Phytomedicine. 23:1680–1690. 2016. View Article : Google Scholar : PubMed/NCBI
31	Garg H, Suri P, Gupta JC, Talwar GP and Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
32	Altieri DC: Survivin-the inconvenient IAP. Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhang C, Wang W, Liu T, Wu Y, Guo H, Wang P, Tian Q, Wang Y and Yuan Z: Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials. 33:2187–2196. 2012. View Article : Google Scholar : PubMed/NCBI